Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KS Biomedix Holdings PLC

Division of Xenova Group PLC
www.ksbiomedix.com

Latest From KS Biomedix Holdings PLC

Recent Dealmaking (02/2004)

Summarizing the month in European dealmaking.

Alizyme/Takeda: Japan Deals Gather Steam

Alizyme's out-licensing pact with Takeda for Japanese rights to the UK biotech's Phase II anti-obesity compound ATL-962 underscores the practical and funding advantages of a Japanese-market deal as a precursor to negotiating US and European licenses. Opportunities for other European biotechs to do the same may increase: Takeda's willingness to develop a still relatively early-stage compound in a tricky development area highlights Japanese firms' particularly acute need for pipeline products.
BioPharmaceutical Asia Pacific

DanioLabs Ltd.

DanioLabs Ltd. was established in October 2001 to develop new drugs for neuro-ophthalmologic disorders. Frustrated at the lack of effective treatments available in these areas, the company's founder set about using zebrafish models of human disease to identify both novel drug targets and effective new drugs. Zebrafish can be manipulated to provide particularly good models of a number of human diseases, including CNS, ophthalmologic, digestive and cardiovascular system disorders.
BioPharmaceutical Europe

Alizyme: Can Low Risk Last Forever?

Alizyme's GBP16.1 million, barely discounted placing and open offer illustrates its investors' faith in its low-risk business model and maturing pipeline. It also provides leverage for negotiating the out-licensing deals those investors now expect.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Xenova Group PLC
  • Senior Management
  • Contact Info
  • KS Biomedix Holdings PLC
    Phone: (44) 1483 307500
    1 Occam Ct.
    Surrey Research
    Guildford, GU2 7HJ
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register